A matrix-type silicone elastomer vaginal ring providing 28-day continuous release of dapivirine 20 (DPV) -a lead candidate human immunodeficiency virus type 1 (HIV-1) microbicide compound 21 -has recently demonstrated moderate levels of protection in two Phase III clinical studies. Here, 22 next-generation matrix and reservoir-type silicone elastomer vaginal rings are reported for the 23 first time offering simultaneous and continuous in vitro release of DPV and the contraceptive 24 progestin levonorgestrel (LNG) over a period of between 60 and 180 days. For matrix-type 25 vaginal rings comprising initial drug loadings of 100, 150 or 200 mg DPV and 0, 16 or 32mg 26 LNG, Day 1 daily DPV release values were between 4132 and 6113 μg while Day 60 values 27 ranged from 284 to 454 μg. Daily LNG release ranged from 129 to 684 μg on Day 1 and 2-91 μg 28 on Day 60. Core-type rings comprising one or two drug-loaded cores provided extended duration 29 of in vitro release out to 180 days, and maintained daily drug release rates within much narrower 30 windows (either 75-131 μg/day or 37-66 μg/day for DPV, and either 96-150 μg/day or 37-57 31 μg/day for LNG, depending on core ring configuration and ignoring initial lag release effect for 32 LNG) compared with matrix-type rings. The data support the continued development of these 33 devices as multi-purpose prevention technologies (MPTs) for HIV prevention and long-acting 34 contraception. 35 36 3 Abbreviations 37 DAC, dual asymmetric centrifuge; DPV, dapivirine; DSC, differential scanning calorimetry; 38 HIV-1, human immunodeficiency virus type 1; HPLC, high performance liquid chromatography; 39 LNG, levonorgestrel; IPM, International Partnership for Microbicides; MPT, multipurpose 40 prevention technology; NNRTI, non-nucleoside reverse transcriptase inhibitor; STI, sexually 41 transmitted infection; SVF, simulated vaginal fluid 42 43 48 non-nucleoside reverse transcriptase inhibitor (NNRTI) -and intended for 28-day continuous 49 use is being developed by the International Partnership for Microbicides (IPM) (R Karl Malcolm 50 et al., 2012; Nel et al., 2011, 2009). This DPV ring recently completed two Phase III clinical 51 studies (the Aspire Study and The Ring Study) designed to support licensure of the ring for 52
Introduction
Vaginal rings offering sustained or controlled release of antiretroviral drugs have been at the 45 forefront of efforts over recent years to develop microbicide products for prevention of sexual 46 transmission of human immunodeficiency virus type 1 (HIV-1) (Malcolm et al., 2016) . A matrixtype silicone elastomer vaginal ring containing dapivirine (DPV; Figure 1A ) -an experimental mixed (120 s, 3000 rpm). A and B premixes were combined in an overall 1:1 ratio, according to 159 the following procedure: (i) 25 g weights of each premix were alternately added to a large screw-160 cap polypropylene container to a final weight of 100 g; (ii) this active silicone elastomer mixture 161 was hand-mixed for 30 s and then DAC mixed (30 s at 3000 rpm); (iii) this process was repeated 162 four times for each formulation to produce 400 g total of the active mix. The 400 g active mix 163 was transferred to a 500 g polypropylene SEMCO ® injection cartridge designed for use with the Table 2 ) were manufactured using a three-step injection 174 molding process ( Figure 2 ). Each step was similar to that described previously for the 175 manufacture of the matrix-type rings (Section 2.3). However, given their greater complexity, the 176 reservoir-type rings were manufactured on a laboratory-scale injection-molding machine using 177 the DDU-4320 grade of addition-cure silicone elastomer, which offers lower cure temperature, 178 lower viscosity and improved flow characteristics compared to the MED-4870 silicone 179 elastomer. Formulation L reservoir-type rings comprised a full-length DDU-4320 silicone 180 elastomer core containing both solid crystalline micronised DPV and solid crystalline non-micronised LNG, each at a loading of 2% w/w. The drug-loaded core was subsequently 182 overmolded in two steps using custom molds with a drug-free DDU-4320 silicone elastomer 183 sheath (rate-controlling membrane). All mixing procedures were conducted as described for the 184 matrix-type rings. However, cure of the drug-loaded cores was performed at 90 °C for 30 s, 185 producing cores with the following dimensions: 54.9 mm outer diameter, 4.5 mm cross-sectional 186 diameter. The overmolded, non-medicated, rate-controlling membrane was cured at 90 °C for 90 187 s. The fully manufactured core rings had the following dimensions: 58.0 mm outer diameter, 7.6 188 mm cross-sectional diameter. The thickness of the non-medicated membrane was therefore (7.6 -189 4.5) / 2 = 1.55 mm. Formulation M reservoir-type rings were manufactured in the same manner, 190 except with two separate half-length coresone containing only 2% w/w DPV and the other 191 containing only 2% LNG ( were injected (25 µL) onto a Thermo Scientific BDS Hypersil C18 column (150 mm x 4.6 mm, 3 224 µm particle size) fitted with a guard column. The column was held at 25 C and isocratic elution 225 was performed using a mobile phase of 55% 7.7 mM phosphate buffer (pH 3.0) and 45% HPLC-grade acetonitrile (1.2 mL/min) with a run time of 9 min. DPV was detected using a wavelength 227 of 210 nm after 6.2 min, while LNG was detected after 7.7 min using a wavelength of 240 nm. cause the rings to swell and that solvent extraction is not responsible for the release of dapivirine. 286 We also have extensive data to confirm that a conventional permeation-controlled release 287 mechanism operates in this medium. Use of isopropanol/water also permits use of much lower 288 (and more practical) volumes of release media; 100 mL per day is typically used for a human- inspection. Ring weights for all matrix-type ring formulations were close to 8 g (Table 1) . (Tables S1 and S2 ). For all ring formulations containing DPV, DPV release showed a 313 burst release on Day 1 (ranging between 4132 and 6038 µg, depending upon initial DPV loading 314 within the ring) followed by steadily declining daily release quantities with time ( Figure 5A ). By In vitro LNG release from the matrix-type rings is rather more nuanced than that for DPV. In We have recently reported that a hydrosilylation reaction occurs between LNG and the hydride- Table S2 in the Supplementary Material) (P < 0.001 for all comparisons). between ring manufacture and release testing or clinical use to permit equilibration of dissolved 433 drug between core and sheath components; this effect is exacerbated at low curing temperatures. 434 However, this explanation does not account for the very substantial lag effects observed for LNG 435 in the rings of this study. Rather, as postulated previously for the unusual release characteristics 436 observed for the LNG-only matrix-type rings (Rings D and E; Figure 6 ), the lag effect here is 437 most likely attributed to a hydrosilylation reaction between the ethinyl functional group in 438 dissolved LNG molecules and excess silane groups in the silicone elastomer system leading to 439 irreversible chemical binding (Murphy et al., 2016b). LNG release rates steadily increased 440 during the initial release period ( Figure 7B ), suggesting that LNG binding within the non-441 medicated silicone elastomer rate-controlling sheath predominates until all of the excess silane 442 groups have reacted. Thereafter, solubilised LNG molecules diffused through the sheath layer 443 uninhibited resulting in the expected zero-order kinetic profile ( Figure 7B ). After 180 days, total 444 cumulative LNG release was 21.5 and 8.6 mg for Rings L and M ( Figure 7D , Table S3 in the 445 Supplementary Material), respectively, equivalent to 42.0% and 33.4% of initial LNG loading, 446 respectively ( Table S3 in the Supplementary Material). That Ring M comprising the half-length 447 LNG core provides LNG release characteristics that are slightly lower than expected compared 448 to Ring L comprising the full-length core DPV+LNG core ( Table S3 in However, a red dye has been incorporated into the silicone elastomer of the core for illustration 692 purposes only. Note that the core (A) was cut prior to overmolding to compensate for shrinkage 693 upon cooling. 3 * Note the visible gap between the two ends of the core in Ring Formulation L due to the cut made in the 4 core prior to overmolding. For Ring Formulation M, the two separate half-length cores are clearly visible 5 in this image; the white core is the DPV-loaded segment (white appearance due to the use of micronized 6 DPV), while the more transparent core is the LNG-loaded segment (LNG was not micronized; small 7 particles of LNG were clearly visible in the silicone elastomer, although these may not be evident from 8 the image in the table.) 9 
